Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate
Against COVID-19 in Healthy Japanese Adults. Final Report: A Phase 1/2, Placebo-Controlled,
Randomized, and Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults.
Category & Conditions: Coronavirus Disease (COVID-19)
Medicine: PF-07302048 (BNT162)
ClinicalTrials.gov Identifier (NCT): NCT04588480
Protocol ID:
PrintDownloadOpen Plain Language Summary Result: Click here